Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Extension Study of ARO-APOC3 in Adults with Dyslipidemia
2022-001135-85Phase 2Active
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jun 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plozasiran in combined dyslipidaemia, sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Started Jun 2022; status: active.
02
Drugs
plozasiran
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on 2022-001135-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001135-85.